FDA advisors appeared convinced that the benefits of a novel CRISPR therapy for sickle cell disease outweigh the theoretical risks for off-target gene editing
Are you worried about the safety of gene-editing therapies?
Medpage Today® surveys are polls of those who choose to participate and are, therefore, not valid statistical samples, but rather a snapshot of what your colleagues are thinking